Efficacy and safety of Molnupiravir in COVID-19 patients: a systematic review
Author:
Publisher
Springer Science and Business Media LLC
Subject
General Medicine
Link
https://link.springer.com/content/pdf/10.1007/s11845-022-03139-y.pdf
Reference36 articles.
1. Crotty S, Cameron CE, Andino R (2001) RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad Sci U S A 98(12):6895–6900. https://doi.org/10.1073/pnas.111085598
2. Agostini ML, Pruijssers AJ, Chappell JD et al (2019) Small-molecule antiviral β-d-N4-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance. J Virol 26;93(24):e01348-19
3. Toots M, Yoon JJ, Hart M et al (2020) Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model. Transl Res 18:16e28. https://doi.org/10.1016/j.trsl.2019
4. Painter WP, Holman W, Bush JA et al (2021) Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2. Antimicrob Agents Chemother 65(5):e02428-e2520. https://doi.org/10.1128/AAC.02428-20
5. FDA (2022) Fact sheet for healthcare providers: emergency use authorization for molnupiravir (fda.gov). Available from: https://www.fda.gov/media/155054/download
Cited by 17 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Experimental and theoretical study on supramolecular encapsulation of molnupiravir by Cucurbit[7]uril: A potential formulating agent for COVID-19;Journal of Molecular Liquids;2024-02
2. An umbrella review on treatments and therapeutic options for COVID-19;Russian Journal of Infection and Immunity;2023-11-30
3. In Vitro Analysis of SARS-CoV-2 Spike Protein and Ivermectin Interaction;International Journal of Molecular Sciences;2023-11-16
4. Longitudinal study of disease severity and external factors in cognitive failure after COVID-19 among Indonesian population;Scientific Reports;2023-11-08
5. Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system;Frontiers in Pharmacology;2023-10-31
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3